MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.300 +0.050 (+4.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
From Innate Pharma SA
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
Via InvestorPlace
News headline image
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2024 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma: Clarification Regarding SAR443579 Designation
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
From Innate Pharma S.A.
Via Business Wire
News headline image
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story